Dupixent shows potential to be the first biologic to treat COPD

CAR-T Digest - August 2020

March 23, 2023: Dupixent (Dupilumab, SC)/ COPD/ Sanofi: Demonstrated significant reduction in acute exacerbation in the pivotal trial

Phase 3 trial comparing Dupixent to a placebo in adults with uncontrolled COPD & type 2 inflammation, met all primary and secondary endpoints
Dupixent is the first biologic to show a notable decrease (30%) in moderate or severe acute exacerbations as well as notable improvements in lung function, QOL, and COPD respiratory symptoms
Topline data expected in 2025
Trial Results:
- 30% reduction in moderate or severe acute COPD exacerbations
- Improved lung function from baseline by 160 mL at 12 weeks compared to 77 mL for placebo, with the benefit versus placebo sustained through week 52
- Overall AEs were 77%, for Dupixent vs 76% for placebo, with headache, diarrhea, and back pain being common
Another Phase 3 trial with Dupixent and Itepekimab (received fast-track designation from FDA for COPD in current non-smokers) is ongoing